Domp

Take orally, 15-30 minutes before meals. Tablets should be swallowed whole with water.

Domperidone acts as a peripheral dopamine D2 receptor antagonist, primarily in the chemoreceptor trigger zone (CTZ) and the gastrointestinal tract. This action blocks dopamine's inhibitory effects on gastric motility, leading to increased lower esophageal sphincter pressure, improved gastroduodenal peristalsis, and accelerated gastric emptying. Its antiemetic effect is due to antagonism of dopamine receptors in the CTZ.

• Hypersensitivity to domperidone or any component of the formulation.
• Known prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances or underlying cardiac diseases (e.g., congestive heart failure).
• Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin).
• Concomitant use with QT-prolonging drugs.
• Moderate to severe hepatic impairment.
• Patients with prolactin-releasing pituitary tumor (prolactinoma).
• When stimulation of gastrointestinal motility might be harmful, e.g., in gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Store below 30°C. Protect from light and moisture. Keep out of reach of children.

Symptoms of overdose may include drowsiness, disorientation, extrapyramidal reactions (especially in children), and cardiac arrhythmias. Treatment is symptomatic and supportive. Gastric lavage and activated charcoal may be considered. Continuous ECG monitoring is recommended.

Pregnancy Category C. Domperidone should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is excreted in human breast milk; therefore, use in breastfeeding mothers is generally not recommended, or the patient should be advised to discontinue breastfeeding while on treatment.